Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $4
H.C. Wainwright Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Raises Target Price to $7
Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $4
Atossa Therapeutics Analyst Ratings
H.C. Wainwright Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $6
Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $4
H.C. Wainwright Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $6
Atossa Therapeutics Analyst Ratings
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $6.5
Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $4
HC Wainwright & Co. Reiterates Buy on Atossa Therapeutics, Maintains $6 Price Target
HC Wainwright & Co. Reiterates Buy on Atossa Therapeutics, Maintains $6 Price Target
Atossa Therapeutics Analyst Ratings
Atossa Therapeutics Analyst Ratings
Atossa Therapeutics Analyst Ratings
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $6.25
Atossa Therapeutics' Endoxifen Shows Promising Phase 2 Results, Secures Buy Rating
HC Wainwright & Co. Maintains Buy on Atossa Therapeutics, Raises Price Target to $6
Atossa Therapeutics Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Atossa Therapeutics (ATOS), Arbutus Biopharma (ABUS)